Fratnow’s Scientific Advisory Board

Dr. Reife, a former executive in major global pharmaceutical companies and more recently a consultant for large, medium and small pharmaceutical companies ( including interim Chief Medical Officer positions at companies like Neurovance, The Medicines Company and SAGE Therapeutics), assists in Fratnow’s development strategy pertaining to the expanded use of FRAT^® assays in other neurological disease states. Dr. Reife brings a diverse medical background in both private/academic practice and as a senior-level strategy and operational executive spanning the R&D and commercial aspects of complex global pharmaceutical companies. Having extensive international market knowledge and on-the- ground cultural intelligence gained in Europe, Asia-Pacific and Latin America building top-tier global teams that consistently achieve corporate strategic and financial objectives, Dr. Reife advises Fratnow on a number of international strategic initiatives. A former Vice President of Global Medical Affairs at Wyeth Pharmaceuticals, Dr. Reife brings broad experience in developing in/out licensing opportunities, M&A strategy/due diligence, designing relevant clinical studies, and alliance based product development, regulatory compliance, and global new product launches. A Fellow of the American Academy of Neurology, Dr. Reife has obtained a BA from University of Pennsylvania, an MBA from Columbia Business School, and a MD from Columbia University College of Physicians and Surgeons

Dr. Edward Quadros Ph.D is the inventor of Fratnow’s Folate Receptor Antibody Test. Currently, Dr. Quadros serves as a Research Professor at SUNY – Downstate in the Departments of Medicine and Cell Biology. His research interests include biochemical and molecular aspects of vitamin B12 / folate absorption, transport and metabolism; Genetic abnormalities of vitamin B12 / folate dependent pathways; Cellular and metabolic consequences of vitamin B12 and folate deficiencies; Vitamin B12, folate and homocysteine metabolism in the elderly population with cardio-vascular disease and cognitive disorders including Alzheimer’s dementia; Neuropathology of vitamin B12 and folate deficiency; B12, folate status and DNA methylation in the brain. Another area of research actively being pursued in Dr. Quadros’ laboratory is the association of folate receptor autoimmunity with neural tube defect pregnancy and cerebral folate deficiency. Current research is focused on fetal and neonatal brain development and the role of folate and B12 in this process. Dr. Quadros has established a strong link between an autoimmune disorder that produces autoantibodies against the folate receptor alpha, a membrane receptor involved in folate transport to the fetus and to the brain. Extensive research in Dr. Quadros’ laboratory is aimed at understanding the cause and effects of this autoimmune disorder and how best to prevent and treat the pathologic consequences. Another aspect of Dr. Quadros’ research is focused on cancer therapeutics based on vitamin B12 and folate analogs that are anti-metabolites, drug-conjugates and pro-drugs; selective targeting of drugs via the B12 and folate transport proteins and their receptors; vitamin B12 and folate depletion strategies to inhibit cell replication in malignancies utilizing monoclonal antibodies to block cellular uptake of these vitamins and to deliver drugs. Dr. Edward Quadros holds a B.Sc. in Chemistry from the University of Poona, a M.Sc. in Applied Biology from the University of Bombay and a Ph.D in Biochemistry from the University of London.

Dr. Richard Frye is a Child Neurologist and Director of Autism Research at Arkansas Children's Hospital Research Institute. He is an Associate Professor in Pediatrics at the University of Arkansas for Medical Sciences, and Director of the Autism Multispecialty Clinic at Arkansas Children's Hospital. Dr. Frye is a well-recognized expert in the diagnosis and treatment of Autism Spectrum Disorders (ASD) and other developmental disorders. Over the past several years he has completed three clinical studies related to ASD, including an open-label trial examining the metabolic and behavioral effects of tetrahydrobiopterin, a clinical study of the metabolic and genetic characteristics of children with ASD and mitochondrial disease, and a clinical study on the prevalence of the folate receptor alpha autoantibody in children with ASD, as well as the response to leucovorin treatment in ASD children with the folate receptor alpha autoantibody. Dr Frye received a B.A. from Long Island University and earned his MD/PhD from Georgetown University. He completed a residency in Pediatrics at the University of Miami, followed by a residency in Child Neurology and fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children's Hospital Boston. He is board certified by the American Board of Pediatrics, and the American Board of Psychiatry and Neurology with Special Competence in Child Neurology. He is a national leader in autism research. He has authored numerous research publications and book chapters, and serves on several editorial boards of prestigious scientific and medical journals. He is a member of the American Academy of Neurology, American Academy of Pediatrics, International Society for Autism Research, and the Society for Neuroscience. Dr. Frye has a broad background including specific training in neurodevelopmental disorders, physiology, psychology, and biostatistics. He is fellowship trained in Behavioral Neurology and Psychology and has clinical expertise in the assessment, diagnosis, and treatment of children with ASD. As Director of Autism Research at the Arkansas Children’s Hospital his goal is to develop an integrated autism program that includes a multi-specialty autism clinic, a translational research program focusing on biomarkers and clinical-trials, and a basic science program focusing on mitochondrial and redox metabolic metabolism.